Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$132.43 USD

132.43
322,778

+3.19 (2.47%)

Updated Oct 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ITGR or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Why Integer (ITGR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Centene (CNC) Ties Up to Aid Its Marketplace Members in Chicago

by Zacks Equity Research

Centene's (CNC) product - Ambetter of Illinois - along with RUSH aim to provide improved access to quality healthcare services for CNC's members in Chicago, and thereby grow its Marketplace business.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Masimo's (MASI) ORi Favored by Study for PaO2 Information

by Zacks Equity Research

Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

McKesson (MCK) Announces Availability of FDA-Approved Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.

BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod

by Zacks Equity Research

BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.

Cooper Companies (COO) Q4 Earnings In Line, '23 Outlook Raised

by Zacks Equity Research

Cooper Companies' (COO) fourth-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid moderating expenses.

AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome

by Zacks Equity Research

AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.

Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.

3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.

Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact

by Zacks Equity Research

Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.

BD (BDX) Launches Advanced Vascular Access Management System

by Zacks Equity Research

BD's (BDX) SiteRite 9 Ultrasound System is likely to revolutionize vascular care by enhancing clinician efficiency and setting a new standard in first-attempt success.

West Pharmaceutical's (WST) New Launch to Expand Portfolio

by Zacks Equity Research

West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.

Community Health (CYH) Sells Three Florida Facilities for $294M

by Zacks Equity Research

Community Health (CYH) divests three hospitals in Florida to Tampa General Hospital, substantiating its endeavor to intensify its focus on high-growth business areas.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.

McKesson (MCK) Announces Availability of FDA-Cleared Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.